Biosimilar pipelines for South Korean firms: LG Chem and GC Pharma

Biosimilars/General | Posted 09/07/2021 post-comment0 Post your comment

Biosimilar makers from South Korea are making their mark, not only in South Korea, but around the world when it comes to biosimilars. Celltrion Healthcare (Celltrion) and Samsung Bioepis (Samsung and Biogen’s joint venture) are already becoming major players in the world of biosimilars. While, other Korean companies, such as LG Chem Life Sciences (LG Chem) and GC Pharma (formerly Green Cross) are also expanding their biosimilar pipelines.

12 AA010179

LG Chem has two biosimilars, one of which, Eucept (etanercept) is already approved in both Japan and South Korea. While LG Pharma has one insulin glargine biosimilar, Glarzia, approved in South Korea, see Table 1.

Table 1: Biosimilar pipelines for South Korean firms: LG Chem and GC Pharma
Company Product name Active substance Therapeutic area Stage of development
LG Chem Eucept (LBEC0101) etanercept Ankylosing spondylitis
Juvenile rheumatoid arthritis
Psoriasis
Psoriatic arthritis
Rheumatoid arthritis
Approved in Japan and South Korea [1]
LR19055 adalimumab Psoriasis
Psoriatic arthritis
Juvenile idiopathic arthritis
Rheumatoid arthritis
Ulcerative colitis
Phase III
GC Pharma Glargia insulin glargine Diabetes Approved in South Korea [2]

  
Eucept was the third etanercept biosimilar to be approved in South Korea. Hanwha Chemical received approval for Davictrel back in November 2014 and Samsung Bioepis received approval for Etolace (Brenzys) in September 2015 [3]. While Glargia was the second insulin glargine biosimilar approval in South Korea, after Eli Lilly/Boehringer Ingelheim’s Basaglar, which was approved in November 2015 [3].

Related articles
Biosimilar pipelines: Chong Kun Dang, DM Bio and HK inno.N

Biosimilar pipelines: Celltrion and Samsung Bioepis

Approved biosimilars for South Korean firms: Celltrion and Samsung Bioepis

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares en Japón: una perspectiva general

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares en Japón: una perspectiva general

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
References
1. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of etanercept [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 9]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-etanercept 
2. GaBI Online - Generics and Biosimilars Initiative. Biosimilars of insulin glargine [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 9]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-of-insulin-glargine 
3. GaBI Online - Generics and Biosimilars Initiative. Biosimilars approved in South Korea [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Jul 9]. Available from: www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-South-Korea

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Off-patent biologicals/Biomimics approved in Bolivia
AGEMED V21I17MN
Biosimilars/General Posted 17/09/2021
Glosario de términos principales
20 AA010933
Biosimilars/General Posted 10/09/2021
Interactive map for interchangeable biosimilars
US map V18D13
Biosimilars/General Posted 10/09/2021
Biosimilars approved in Costa Rica
MinSalud Costa Rica V21I03
Biosimilars/General Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010